An observational study in Metastatic Colorectal Cancer, Metastatic Cervical Cancer and Non Squamous Non Small Cell Lung Cancer, sponsored by Laboratorios Liomont. Completed at 5 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.
Sponsored by Laboratorios Liomont · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Colorectal Neoplasms with a site in Mexico — 8 open to participants now, 10 under way, 6 of them phase 3. Colorectal Neoplasms · Mexico.
Among the 29 studies in Colorectal Neoplasms with a site in Mexico, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 21st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →8 of the 29 studies in Colorectal Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in Mexico, United States
Ages 18+
Bristol-Myers Squibb · Sites in Mexico, United States, Argentina and 22 more countries
Ages 18+
Summit Therapeutics · Sites in Mexico, United States, Belgium and 12 more countries
Ages 18+
GlaxoSmithKline · Sites in Mexico, United States, Australia and 16 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Mexico, United States, Australia and 23 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 18 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 700 across the 25 interventional studies, 1,034 across the 3 observational. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 29 have an industry lead sponsor. The 10 most frequent:
Laboratorios Liomont is the lead sponsor of 4 studies on the registry; none are open to participants now.
Laboratorios Liomont has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Colorectal Neoplasms with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
Naive to bevacizumab, adult patients with metastatic colorectal cancer, metastatic cervical cancer, non-squamous non-small cell lung cancer, and other cancer types where Bevacizumab therapy is indicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bevacizumab (Effivia®)
Drug: Bevacizumab Biosimilar MB02
5 mg/kg to 15 mg/kg in combination with chemotherapy.
Also known as: Effivia®
Adverse events
Frequency and characteristics of adverse events (serious and non serious)
Time frame: From date of patient inclusion to the end of Cycle 1 (each cycle is up to six months)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Apr 2024, 20 months.
Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 20 months is below that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratorios Liomont